Jump to section

References

Trials

Economics

Properties

Spectra

Taxonomy

Salicylamide

Identification

Name

Salicylamide

Accession Number

DB08797

Type

Small Molecule

Groups

Approved

Description

Salicylamide is the common name for the substance o-hydroxybenzamide, or amide of salicyl. Salicylamide is a non-prescription drug with analgesic and antipyretic properties. Its medicinal uses are similar to those of aspirin. Salicylamide is used in combination with both aspirin and caffeine in the over-the-counter pain remedies

Structure

Similar Structures

Synonyms

2-Carbamoylphenol
2-Carboxamidophenol
2-Hydroxybenzamide
o-hydroxybenzamide
OHB
Salicilamida
Salicylamidum
Salicylic acid amide

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Exaprin	Salicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1)	Tablet	Oral	HART Health	1987-01-20	Not applicable
Extra Strength Pain Reliever	Salicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1)	Tablet	Oral	Redicare Llc	2017-10-01	Not applicable
Green Guard Pain and Ache Relief	Salicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1)	Tablet	Oral	Unifirst First Aid	2008-12-30	Not applicable
Medi First Pain Relief	Salicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1)	Tablet	Oral	Unifirst First Aid	2008-12-30	Not applicable
Medi First Plus Pain Zapper	Salicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1)	Tablet	Oral	Unifirst First Aid	2008-12-30	Not applicable
Pain Free	Salicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1)	Tablet	Oral	Afassco Inc.	2016-10-25	Not applicable
Pain Reliever	Salicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1)	Tablet	Oral	Advanced First Aid, Inc.	2015-04-07	Not applicable
Pain Stopper Extra	Salicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1)	Tablet	Oral	North Safety Products	2012-03-07	2017-12-22
Pain Stoppers	Salicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1)	Tablet	Oral	North Safety Products	2017-01-02	Not applicable
Pain Stoppers Regular	Salicylamide (152 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Caffeine (32.4 mg/1)	Tablet	Oral	North Safety Products	2013-04-18	2017-12-22

Categories

UNII

EM8BM710ZC

CAS number

65-45-2

Weight

Average: 137.136
Monoisotopic: 137.047678473

Chemical Formula

C₇H₇NO₂

InChI Key

SKZKKFZAGNVIMN-UHFFFAOYSA-N

InChI

InChI=1S/C7H7NO2/c8-7(10)5-3-1-2-4-6(5)9/h1-4,9H,(H2,8,10)

IUPAC Name

2-hydroxybenzamide

SMILES

NC(=O)C1=CC=CC=C1O

Pharmacology

Indication

Not Available

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Oral, rat LD50: 1890 mg/kg

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
(4R)-limonene	The risk or severity of adverse effects can be increased when Salicylamide is combined with (4R)-limonene.	Investigational
16-Bromoepiandrosterone	The risk or severity of adverse effects can be increased when Salicylamide is combined with 16-Bromoepiandrosterone.	Investigational
19-norandrostenedione	The risk or severity of adverse effects can be increased when Salicylamide is combined with 19-norandrostenedione.	Experimental, Illicit
5-androstenedione	The risk or severity of adverse effects can be increased when Salicylamide is combined with 5-androstenedione.	Experimental, Illicit
Abciximab	Salicylamide may increase the anticoagulant activities of Abciximab.	Approved
Acebutolol	Salicylamide may decrease the antihypertensive activities of Acebutolol.	Approved, Investigational
Aceclofenac	The risk or severity of adverse effects can be increased when Salicylamide is combined with Aceclofenac.	Approved, Investigational
Acemetacin	The risk or severity of adverse effects can be increased when Salicylamide is combined with Acemetacin.	Approved, Experimental, Investigational
Acenocoumarol	Salicylamide may increase the anticoagulant activities of Acenocoumarol.	Approved, Investigational
Acetylsalicylic acid	The risk or severity of adverse effects can be increased when Salicylamide is combined with Acetylsalicylic acid.	Approved, Vet Approved
Adapalene	The risk or severity of adverse effects can be increased when Adapalene is combined with Salicylamide.	Approved
Alclofenac	The risk or severity of adverse effects can be increased when Salicylamide is combined with Alclofenac.	Approved, Withdrawn
Alclometasone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Alclometasone.	Approved
Aldosterone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Aldosterone.	Experimental, Investigational
Alendronic acid	The risk or severity of adverse effects can be increased when Salicylamide is combined with Alendronic acid.	Approved
Aliskiren	Salicylamide may decrease the antihypertensive activities of Aliskiren.	Approved, Investigational
Alminoprofen	The risk or severity of adverse effects can be increased when Salicylamide is combined with Alminoprofen.	Experimental
Alprenolol	Salicylamide may decrease the antihypertensive activities of Alprenolol.	Approved, Withdrawn
Alprostadil	The therapeutic efficacy of Alprostadil can be decreased when used in combination with Salicylamide.	Approved, Investigational
Amcinonide	The risk or severity of adverse effects can be increased when Salicylamide is combined with Amcinonide.	Approved
Amikacin	The risk or severity of nephrotoxicity can be increased when Salicylamide is combined with Amikacin.	Approved, Investigational, Vet Approved
Amiloride	Salicylamide may decrease the antihypertensive activities of Amiloride.	Approved
Aminosalicylic Acid	The risk or severity of adverse effects can be increased when Salicylamide is combined with Aminosalicylic Acid.	Approved
Amlodipine	The therapeutic efficacy of Amlodipine can be decreased when used in combination with Salicylamide.	Approved
Ancrod	Salicylamide may increase the anticoagulant activities of Ancrod.	Approved, Investigational
Andrographolide	The risk or severity of adverse effects can be increased when Andrographolide is combined with Salicylamide.	Investigational
Androstenedione	The risk or severity of adverse effects can be increased when Salicylamide is combined with Androstenedione.	Experimental, Illicit
Anecortave	The risk or severity of adverse effects can be increased when Salicylamide is combined with Anecortave.	Investigational
anecortave acetate	The risk or severity of adverse effects can be increased when Salicylamide is combined with anecortave acetate.	Investigational
Anisodamine	The risk or severity of adverse effects can be increased when Salicylamide is combined with Anisodamine.	Investigational
Antipyrine	The risk or severity of adverse effects can be increased when Salicylamide is combined with Antipyrine.	Approved, Investigational
Antithrombin III human	Salicylamide may increase the anticoagulant activities of Antithrombin III human.	Approved
Antrafenine	The risk or severity of adverse effects can be increased when Salicylamide is combined with Antrafenine.	Approved
Apixaban	Salicylamide may increase the anticoagulant activities of Apixaban.	Approved
Apocynin	The risk or severity of adverse effects can be increased when Salicylamide is combined with Apocynin.	Investigational
Apramycin	Salicylamide may decrease the excretion rate of Apramycin which could result in a higher serum level.	Experimental, Vet Approved
Apremilast	The risk or severity of adverse effects can be increased when Apremilast is combined with Salicylamide.	Approved, Investigational
Arbekacin	Salicylamide may decrease the excretion rate of Arbekacin which could result in a higher serum level.	Approved, Investigational
Ardeparin	Salicylamide may increase the anticoagulant activities of Ardeparin.	Approved, Investigational, Withdrawn
Argatroban	Salicylamide may increase the anticoagulant activities of Argatroban.	Approved, Investigational
Arotinolol	Salicylamide may decrease the antihypertensive activities of Arotinolol.	Investigational
Asenapine	Salicylamide may decrease the antihypertensive activities of Asenapine.	Approved
Atamestane	The risk or severity of adverse effects can be increased when Salicylamide is combined with Atamestane.	Investigational
Atenolol	Salicylamide may decrease the antihypertensive activities of Atenolol.	Approved
Azapropazone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Salicylamide.	Withdrawn
Azelastine	The risk or severity of adverse effects can be increased when Azelastine is combined with Salicylamide.	Approved
Azficel-T	The risk or severity of adverse effects can be increased when Salicylamide is combined with Azficel-T.	Approved, Investigational
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Salicylamide.	Approved, Investigational
Azosemide	The therapeutic efficacy of Azosemide can be decreased when used in combination with Salicylamide.	Investigational
Bacitracin	The risk or severity of nephrotoxicity can be increased when Salicylamide is combined with Bacitracin.	Approved, Vet Approved
Balsalazide	The risk or severity of adverse effects can be increased when Salicylamide is combined with Balsalazide.	Approved, Investigational
Becaplermin	Salicylamide may increase the anticoagulant activities of Becaplermin.	Approved, Investigational
Beclomethasone dipropionate	The risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Salicylamide.	Approved, Investigational
Befunolol	Salicylamide may decrease the antihypertensive activities of Befunolol.	Experimental
Bekanamycin	Salicylamide may decrease the excretion rate of Bekanamycin which could result in a higher serum level.	Experimental
Benazepril	The risk or severity of adverse effects can be increased when Salicylamide is combined with Benazepril.	Approved, Investigational
Bendazac	The risk or severity of adverse effects can be increased when Salicylamide is combined with Bendazac.	Experimental
Bendroflumethiazide	The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Salicylamide.	Approved
Benorilate	The risk or severity of adverse effects can be increased when Salicylamide is combined with Benorilate.	Experimental
Benoxaprofen	The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Salicylamide.	Withdrawn
Benzthiazide	The therapeutic efficacy of Benzthiazide can be decreased when used in combination with Salicylamide.	Approved
Benzydamine	The risk or severity of adverse effects can be increased when Salicylamide is combined with Benzydamine.	Approved
Bepridil	The therapeutic efficacy of Bepridil can be decreased when used in combination with Salicylamide.	Approved, Withdrawn
Beraprost	The therapeutic efficacy of Beraprost can be decreased when used in combination with Salicylamide.	Investigational
Betamethasone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Betamethasone.	Approved, Vet Approved
Betaxolol	Salicylamide may decrease the antihypertensive activities of Betaxolol.	Approved, Investigational
Betrixaban	The risk or severity of bleeding can be increased when Betrixaban is combined with Salicylamide.	Approved, Investigational
Bevantolol	Salicylamide may decrease the antihypertensive activities of Bevantolol.	Approved
Bevonium	The risk or severity of adverse effects can be increased when Salicylamide is combined with Bevonium.	Experimental
Bimatoprost	The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Salicylamide.	Approved, Investigational
Bisoprolol	Salicylamide may decrease the antihypertensive activities of Bisoprolol.	Approved
Bivalirudin	Salicylamide may increase the anticoagulant activities of Bivalirudin.	Approved, Investigational
Bopindolol	Salicylamide may decrease the antihypertensive activities of Bopindolol.	Approved
Bromfenac	The risk or severity of adverse effects can be increased when Salicylamide is combined with Bromfenac.	Approved
Bucillamine	The risk or severity of adverse effects can be increased when Salicylamide is combined with Bucillamine.	Investigational
Bucindolol	Salicylamide may decrease the antihypertensive activities of Bucindolol.	Investigational
Budesonide	The risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Salicylamide.	Approved
Bufexamac	The risk or severity of adverse effects can be increased when Salicylamide is combined with Bufexamac.	Approved, Experimental
Bufuralol	Salicylamide may decrease the antihypertensive activities of Bufuralol.	Experimental, Investigational
Bumadizone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Bumadizone.	Experimental
Bumetanide	The therapeutic efficacy of Bumetanide can be decreased when used in combination with Salicylamide.	Approved
Bupranolol	Salicylamide may decrease the antihypertensive activities of Bupranolol.	Approved
Candesartan	The risk or severity of adverse effects can be increased when Candesartan is combined with Salicylamide.	Experimental
Candesartan cilexetil	The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Salicylamide.	Approved
Candoxatril	The risk or severity of adverse effects can be increased when Salicylamide is combined with Candoxatril.	Experimental
Capsaicin	The risk or severity of adverse effects can be increased when Salicylamide is combined with Capsaicin.	Approved
Captopril	The risk or severity of adverse effects can be increased when Salicylamide is combined with Captopril.	Approved
Carbaspirin calcium	The risk or severity of adverse effects can be increased when Salicylamide is combined with Carbaspirin calcium.	Experimental, Investigational
Carboprost Tromethamine	The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Salicylamide.	Approved
Carprofen	The risk or severity of adverse effects can be increased when Salicylamide is combined with Carprofen.	Approved, Vet Approved, Withdrawn
Carteolol	Salicylamide may decrease the antihypertensive activities of Carteolol.	Approved
Carvedilol	Salicylamide may decrease the antihypertensive activities of Carvedilol.	Approved, Investigational
Castanospermine	The risk or severity of adverse effects can be increased when Castanospermine is combined with Salicylamide.	Experimental
Celecoxib	The risk or severity of adverse effects can be increased when Salicylamide is combined with Celecoxib.	Approved, Investigational
Celiprolol	Salicylamide may decrease the antihypertensive activities of Celiprolol.	Approved, Investigational
Certoparin	Salicylamide may increase the anticoagulant activities of Certoparin.	Approved, Investigational
Chloroquine	The risk or severity of adverse effects can be increased when Chloroquine is combined with Salicylamide.	Approved, Investigational, Vet Approved
Chlorothiazide	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Salicylamide.	Approved, Vet Approved
Chlorphenesin	The risk or severity of adverse effects can be increased when Salicylamide is combined with Chlorphenesin.	Approved, Vet Approved, Withdrawn
Chlorthalidone	The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Salicylamide.	Approved
Cholestyramine	Cholestyramine can cause a decrease in the absorption of Salicylamide resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Choline magnesium trisalicylate	The risk or severity of adverse effects can be increased when Salicylamide is combined with Choline magnesium trisalicylate.	Approved
Ciclesonide	The risk or severity of adverse effects can be increased when Salicylamide is combined with Ciclesonide.	Approved, Investigational
Cilazapril	The risk or severity of adverse effects can be increased when Salicylamide is combined with Cilazapril.	Approved
Cimicoxib	The risk or severity of adverse effects can be increased when Salicylamide is combined with Cimicoxib.	Investigational
Cinoxacin	Salicylamide may increase the neuroexcitatory activities of Cinoxacin.	Approved, Investigational, Withdrawn
Ciprofloxacin	Salicylamide may increase the neuroexcitatory activities of Ciprofloxacin.	Approved, Investigational
Cisplatin	The risk or severity of adverse effects can be increased when Salicylamide is combined with Cisplatin.	Approved
Clobetasol	The risk or severity of adverse effects can be increased when Salicylamide is combined with Clobetasol.	Approved, Investigational
Clobetasol propionate	The risk or severity of adverse effects can be increased when Salicylamide is combined with Clobetasol propionate.	Approved
Clobetasone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Clobetasone.	Approved
Clocortolone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Clocortolone.	Approved
Clodronic Acid	The risk or severity of adverse effects can be increased when Salicylamide is combined with Clodronic Acid.	Approved, Investigational, Vet Approved
Clonixin	The risk or severity of adverse effects can be increased when Salicylamide is combined with Clonixin.	Approved
Cloprostenol	The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Salicylamide.	Vet Approved
Cloranolol	Salicylamide may decrease the antihypertensive activities of Cloranolol.	Experimental
Colesevelam	Colesevelam can cause a decrease in the absorption of Salicylamide resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Colestipol	Colestipol can cause a decrease in the absorption of Salicylamide resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Cortexolone 17α-propionate	The risk or severity of adverse effects can be increased when Salicylamide is combined with Cortexolone 17α-propionate.	Investigational
Corticosterone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Corticosterone.	Experimental
Cortisone acetate	The risk or severity of adverse effects can be increased when Salicylamide is combined with Cortisone acetate.	Approved, Investigational
Curcumin	The risk or severity of adverse effects can be increased when Salicylamide is combined with Curcumin.	Approved, Investigational
Cyclopenthiazide	The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Salicylamide.	Experimental
Cyclosporine	The risk or severity of renal failure and hypertension can be increased when Salicylamide is combined with Cyclosporine.	Approved, Investigational, Vet Approved
Dabigatran etexilate	Salicylamide may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Dalteparin	Salicylamide may increase the anticoagulant activities of Dalteparin.	Approved
Danaparoid	Salicylamide may increase the anticoagulant activities of Danaparoid.	Approved, Withdrawn
Darexaban	Salicylamide may increase the anticoagulant activities of Darexaban.	Investigational
Deferasirox	The risk or severity of adverse effects can be increased when Salicylamide is combined with Deferasirox.	Approved, Investigational
Deflazacort	The risk or severity of adverse effects can be increased when Salicylamide is combined with Deflazacort.	Approved, Investigational
Delapril	The risk or severity of adverse effects can be increased when Salicylamide is combined with Delapril.	Investigational
Desipramine	Salicylamide may decrease the antihypertensive activities of Desipramine.	Approved, Investigational
Desirudin	Salicylamide may increase the anticoagulant activities of Desirudin.	Approved
Desmopressin	The risk or severity of adverse effects can be increased when Salicylamide is combined with Desmopressin.	Approved
Desonide	The risk or severity of adverse effects can be increased when Salicylamide is combined with Desonide.	Approved, Investigational
Desoximetasone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Desoximetasone.	Approved
Desoxycorticosterone acetate	The risk or severity of adverse effects can be increased when Salicylamide is combined with Desoxycorticosterone acetate.	Approved
Desoxycorticosterone Pivalate	The risk or severity of adverse effects can be increased when Salicylamide is combined with Desoxycorticosterone Pivalate.	Experimental, Vet Approved
Dexamethasone	The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Salicylamide.	Approved, Investigational, Vet Approved
Dexamethasone isonicotinate	The risk or severity of adverse effects can be increased when Salicylamide is combined with Dexamethasone isonicotinate.	Vet Approved
Dexibuprofen	The risk or severity of adverse effects can be increased when Salicylamide is combined with Dexibuprofen.	Approved, Investigational
Dexketoprofen	The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Salicylamide.	Approved, Investigational
Dexniguldipine	The therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Salicylamide.	Experimental
Dextran	Salicylamide may increase the anticoagulant activities of Dextran.	Approved, Investigational, Vet Approved
Dibekacin	Salicylamide may decrease the excretion rate of Dibekacin which could result in a higher serum level.	Experimental
Dibotermin alfa	The risk or severity of adverse effects can be increased when Salicylamide is combined with Dibotermin alfa.	Approved, Investigational
Diclofenac	The risk or severity of adverse effects can be increased when Diclofenac is combined with Salicylamide.	Approved, Vet Approved
Dicoumarol	Salicylamide may increase the anticoagulant activities of Dicoumarol.	Approved
Difenpiramide	The risk or severity of adverse effects can be increased when Salicylamide is combined with Difenpiramide.	Experimental
Diflorasone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Diflorasone.	Approved
Diflunisal	The risk or severity of adverse effects can be increased when Salicylamide is combined with Diflunisal.	Approved, Investigational
Difluocortolone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Difluocortolone.	Approved, Investigational, Withdrawn
Difluprednate	The risk or severity of adverse effects can be increased when Salicylamide is combined with Difluprednate.	Approved
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Salicylamide.	Approved
Dihydrostreptomycin	Salicylamide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.	Investigational, Vet Approved
Diltiazem	The therapeutic efficacy of Diltiazem can be decreased when used in combination with Salicylamide.	Approved, Investigational
Dinoprost	The therapeutic efficacy of Dinoprost can be decreased when used in combination with Salicylamide.	Investigational
Dinoprost Tromethamine	The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Salicylamide.	Approved, Vet Approved
Dinoprostone	The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Salicylamide.	Approved
Doxazosin	The therapeutic efficacy of Doxazosin can be decreased when used in combination with Salicylamide.	Approved
Drospirenone	Salicylamide may increase the hyperkalemic activities of Drospirenone.	Approved
Droxicam	The risk or severity of adverse effects can be increased when Salicylamide is combined with Droxicam.	Withdrawn
Duvelisib	The risk or severity of adverse effects can be increased when Salicylamide is combined with Duvelisib.	Investigational
E-6201	The risk or severity of adverse effects can be increased when Salicylamide is combined with E-6201.	Investigational
Edetic Acid	Salicylamide may increase the anticoagulant activities of Edetic Acid.	Approved, Vet Approved
Edoxaban	Salicylamide may increase the anticoagulant activities of Edoxaban.	Approved
Efonidipine	The therapeutic efficacy of Efonidipine can be decreased when used in combination with Salicylamide.	Approved, Investigational
Enalapril	The risk or severity of adverse effects can be increased when Salicylamide is combined with Enalapril.	Approved, Vet Approved
Enalaprilat	The risk or severity of adverse effects can be increased when Salicylamide is combined with Enalaprilat.	Approved
Enoxacin	Salicylamide may increase the neuroexcitatory activities of Enoxacin.	Approved, Investigational
Enoxaparin	Salicylamide may increase the anticoagulant activities of Enoxaparin.	Approved
Enprostil	The therapeutic efficacy of Enprostil can be decreased when used in combination with Salicylamide.	Experimental
Epanolol	Salicylamide may decrease the antihypertensive activities of Epanolol.	Experimental
Epirizole	The risk or severity of adverse effects can be increased when Salicylamide is combined with Epirizole.	Approved
Epitizide	The therapeutic efficacy of Epitizide can be decreased when used in combination with Salicylamide.	Experimental
Eplerenone	Salicylamide may decrease the antihypertensive activities of Eplerenone.	Approved
Epoprostenol	The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Salicylamide.	Approved
Eprosartan	The risk or severity of adverse effects can be increased when Eprosartan is combined with Salicylamide.	Approved
Equilenin	The risk or severity of adverse effects can be increased when Salicylamide is combined with Equilenin.	Experimental
Equilin	The risk or severity of adverse effects can be increased when Salicylamide is combined with Equilin.	Approved
Esatenolol	Salicylamide may decrease the antihypertensive activities of Esatenolol.	Experimental
Esmolol	Salicylamide may decrease the antihypertensive activities of Esmolol.	Approved
Estrone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Estrone.	Approved
Estrone sulfate	The risk or severity of adverse effects can be increased when Salicylamide is combined with Estrone sulfate.	Approved
Etacrynic acid	The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Salicylamide.	Approved, Investigational
Etanercept	The risk or severity of adverse effects can be increased when Salicylamide is combined with Etanercept.	Approved, Investigational
Ethenzamide	The risk or severity of adverse effects can be increased when Salicylamide is combined with Ethenzamide.	Experimental
Ethyl biscoumacetate	Salicylamide may increase the anticoagulant activities of Ethyl biscoumacetate.	Withdrawn
Etidronic acid	The risk or severity of adverse effects can be increased when Salicylamide is combined with Etidronic acid.	Approved
Etodolac	The risk or severity of adverse effects can be increased when Salicylamide is combined with Etodolac.	Approved, Investigational, Vet Approved
Etofenamate	The risk or severity of adverse effects can be increased when Salicylamide is combined with Etofenamate.	Approved, Investigational
Etoricoxib	The risk or severity of adverse effects can be increased when Salicylamide is combined with Etoricoxib.	Approved, Investigational
Evening primrose oil	The risk or severity of adverse effects can be increased when Salicylamide is combined with Evening primrose oil.	Investigational, Nutraceutical
Exisulind	The risk or severity of adverse effects can be increased when Exisulind is combined with Salicylamide.	Investigational
Felbinac	The risk or severity of adverse effects can be increased when Felbinac is combined with Salicylamide.	Experimental
Felodipine	The therapeutic efficacy of Felodipine can be decreased when used in combination with Salicylamide.	Approved, Investigational
Fenbufen	The risk or severity of adverse effects can be increased when Salicylamide is combined with Fenbufen.	Approved
Fenoprofen	The risk or severity of adverse effects can be increased when Salicylamide is combined with Fenoprofen.	Approved
Fenprostalene	The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Salicylamide.	Vet Approved
Fentiazac	The risk or severity of adverse effects can be increased when Salicylamide is combined with Fentiazac.	Experimental
Feprazone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Feprazone.	Experimental
Ferulic acid	Salicylamide may increase the anticoagulant activities of Ferulic acid.	Experimental
Fimasartan	The risk or severity of adverse effects can be increased when Fimasartan is combined with Salicylamide.	Approved, Investigational
Fleroxacin	Salicylamide may increase the neuroexcitatory activities of Fleroxacin.	Approved
Floctafenine	The risk or severity of adverse effects can be increased when Floctafenine is combined with Salicylamide.	Approved, Withdrawn
Fluasterone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Fluasterone.	Investigational
Fludrocortisone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Fludrocortisone.	Approved, Investigational
Fluindione	Salicylamide may increase the anticoagulant activities of Fluindione.	Approved, Investigational
Flumequine	Salicylamide may increase the neuroexcitatory activities of Flumequine.	Withdrawn
Flumethasone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Flumethasone.	Approved, Vet Approved
Flunisolide	The risk or severity of adverse effects can be increased when Salicylamide is combined with Flunisolide.	Approved, Investigational
Flunixin	The risk or severity of adverse effects can be increased when Salicylamide is combined with Flunixin.	Vet Approved
Flunoxaprofen	The risk or severity of adverse effects can be increased when Salicylamide is combined with Flunoxaprofen.	Experimental
Fluocinolone Acetonide	The risk or severity of adverse effects can be increased when Salicylamide is combined with Fluocinolone Acetonide.	Approved, Investigational, Vet Approved
Fluocinonide	The risk or severity of adverse effects can be increased when Salicylamide is combined with Fluocinonide.	Approved, Investigational
Fluocortolone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Fluocortolone.	Approved, Withdrawn
Fluorometholone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Fluorometholone.	Approved, Investigational
Fluprednidene	The risk or severity of adverse effects can be increased when Salicylamide is combined with Fluprednidene.	Approved, Withdrawn
Fluprednisolone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Fluprednisolone.	Approved
Fluprostenol	The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Salicylamide.	Vet Approved
Flurandrenolide	The risk or severity of adverse effects can be increased when Salicylamide is combined with Flurandrenolide.	Approved
Flurbiprofen	The risk or severity of adverse effects can be increased when Salicylamide is combined with Flurbiprofen.	Approved, Investigational
Fluticasone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Fluticasone.	Approved, Experimental, Investigational
Fluticasone furoate	The risk or severity of adverse effects can be increased when Salicylamide is combined with Fluticasone furoate.	Approved
Fluticasone propionate	The risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Salicylamide.	Approved
Folic Acid	The therapeutic efficacy of Folic Acid can be decreased when used in combination with Salicylamide.	Approved, Nutraceutical, Vet Approved
Fondaparinux	Salicylamide may increase the anticoagulant activities of Fondaparinux sodium.	Approved, Investigational
Forasartan	The risk or severity of adverse effects can be increased when Forasartan is combined with Salicylamide.	Experimental
Formestane	The risk or severity of adverse effects can be increased when Salicylamide is combined with Formestane.	Approved, Investigational, Withdrawn
Fosinopril	The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylamide is combined with Fosinopril.	Approved
Framycetin	Salicylamide may decrease the excretion rate of Framycetin which could result in a higher serum level.	Approved
Furosemide	The therapeutic efficacy of Furosemide can be decreased when used in combination with Salicylamide.	Approved, Vet Approved
Gabexate	Salicylamide may increase the anticoagulant activities of Gabexate.	Investigational
Garenoxacin	Salicylamide may increase the neuroexcitatory activities of Garenoxacin.	Investigational
Gatifloxacin	Salicylamide may increase the neuroexcitatory activities of Gatifloxacin.	Approved, Investigational
Gemeprost	The therapeutic efficacy of Gemeprost can be decreased when used in combination with Salicylamide.	Approved, Withdrawn
Gemifloxacin	Salicylamide may increase the neuroexcitatory activities of Gemifloxacin.	Approved, Investigational
Geneticin	Salicylamide may decrease the excretion rate of Geneticin which could result in a higher serum level.	Experimental
Gentamicin	Salicylamide may decrease the excretion rate of Gentamicin which could result in a higher serum level.	Approved, Vet Approved
GENTAMICIN C1A	Salicylamide may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.	Experimental
Ginseng	The risk or severity of adverse effects can be increased when Salicylamide is combined with Ginseng.	Approved, Investigational, Nutraceutical
Glipizide	The protein binding of Glipizide can be decreased when combined with Salicylamide.	Approved, Investigational
Glyburide	The protein binding of Glyburide can be decreased when combined with Salicylamide.	Approved
Grepafloxacin	Salicylamide may increase the neuroexcitatory activities of Grepafloxacin.	Approved, Investigational, Withdrawn
Guacetisal	The risk or severity of adverse effects can be increased when Salicylamide is combined with Guacetisal.	Experimental
Guanfacine	The therapeutic efficacy of Guanfacine can be decreased when used in combination with Salicylamide.	Approved, Investigational
Halcinonide	The risk or severity of adverse effects can be increased when Salicylamide is combined with Halcinonide.	Approved, Investigational, Withdrawn
Haloperidol	The risk or severity of adverse effects can be increased when Salicylamide is combined with Haloperidol.	Approved
HE3286	The risk or severity of adverse effects can be increased when Salicylamide is combined with HE3286.	Investigational
Heparin	Salicylamide may increase the anticoagulant activities of Heparin.	Approved, Investigational
Higenamine	The risk or severity of adverse effects can be increased when Salicylamide is combined with Higenamine.	Investigational
Hydralazine	Salicylamide may decrease the antihypertensive activities of Hydralazine.	Approved
Hydrochlorothiazide	The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Salicylamide.	Approved, Vet Approved
Hydrocortisone	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Salicylamide.	Approved, Vet Approved
Hydrocortisone acetate	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Salicylamide.	Approved, Vet Approved
Hydrocortisone butyrate	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Salicylamide.	Approved, Vet Approved
Hydroflumethiazide	The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Salicylamide.	Approved, Investigational
Hygromycin B	Salicylamide may decrease the excretion rate of Hygromycin B which could result in a higher serum level.	Vet Approved
Ibandronate	The risk or severity of gastrointestinal bleeding can be increased when Salicylamide is combined with Ibandronate.	Approved, Investigational
Ibuprofen	The risk or severity of adverse effects can be increased when Ibuprofen is combined with Salicylamide.	Approved
Ibuproxam	The risk or severity of adverse effects can be increased when Salicylamide is combined with Ibuproxam.	Withdrawn
Icatibant	The risk or severity of adverse effects can be increased when Icatibant is combined with Salicylamide.	Approved, Investigational
Icosapent	The risk or severity of adverse effects can be increased when Salicylamide is combined with Icosapent.	Approved, Nutraceutical
Idraparinux	Salicylamide may increase the anticoagulant activities of Idraparinux.	Investigational
Iloprost	The therapeutic efficacy of Iloprost can be decreased when used in combination with Salicylamide.	Approved, Investigational
Imidapril	The risk or severity of adverse effects can be increased when Salicylamide is combined with Imidapril.	Investigational
Imidazole salicylate	The risk or severity of adverse effects can be increased when Salicylamide is combined with Imidazole salicylate.	Experimental
Indapamide	The therapeutic efficacy of Indapamide can be decreased when used in combination with Salicylamide.	Approved
Indenolol	Salicylamide may decrease the antihypertensive activities of Indenolol.	Withdrawn
Indobufen	The risk or severity of adverse effects can be increased when Salicylamide is combined with Indobufen.	Investigational
Indomethacin	The risk or severity of adverse effects can be increased when Salicylamide is combined with Indomethacin.	Approved, Investigational
Indoprofen	The risk or severity of adverse effects can be increased when Salicylamide is combined with Indoprofen.	Withdrawn
Irbesartan	The risk or severity of adverse effects can be increased when Irbesartan is combined with Salicylamide.	Approved, Investigational
Isepamicin	Salicylamide may decrease the excretion rate of Isepamicin which could result in a higher serum level.	Experimental
Isoxicam	The risk or severity of adverse effects can be increased when Salicylamide is combined with Isoxicam.	Withdrawn
Isradipine	The therapeutic efficacy of Isradipine can be decreased when used in combination with Salicylamide.	Approved, Investigational
Istaroxime	The risk or severity of adverse effects can be increased when Salicylamide is combined with Istaroxime.	Investigational
Kanamycin	Salicylamide may decrease the excretion rate of Kanamycin which could result in a higher serum level.	Approved, Investigational, Vet Approved
Kebuzone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Kebuzone.	Experimental
Ketoprofen	The risk or severity of adverse effects can be increased when Salicylamide is combined with Ketoprofen.	Approved, Vet Approved
Ketorolac	The risk or severity of adverse effects can be increased when Ketorolac is combined with Salicylamide.	Approved
Labetalol	Salicylamide may decrease the antihypertensive activities of Labetalol.	Approved
Lacidipine	The therapeutic efficacy of Lacidipine can be decreased when used in combination with Salicylamide.	Approved, Investigational
Landiolol	Salicylamide may decrease the antihypertensive activities of Landiolol.	Investigational
Latanoprost	The therapeutic efficacy of Latanoprost can be decreased when used in combination with Salicylamide.	Approved, Investigational
Latanoprostene Bunod	The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Salicylamide.	Approved, Investigational
Leflunomide	The risk or severity of adverse effects can be increased when Leflunomide is combined with Salicylamide.	Approved, Investigational
Lepirudin	Salicylamide may increase the anticoagulant activities of Lepirudin.	Approved
Lercanidipine	The therapeutic efficacy of Lercanidipine can be decreased when used in combination with Salicylamide.	Approved, Investigational
Letaxaban	Salicylamide may increase the anticoagulant activities of Letaxaban.	Investigational
Levobetaxolol	Salicylamide may decrease the antihypertensive activities of Levobetaxolol.	Approved, Investigational
Levobunolol	Salicylamide may decrease the antihypertensive activities of Levobunolol.	Approved
Levofloxacin	Salicylamide may increase the neuroexcitatory activities of Levofloxacin.	Approved, Investigational
Limaprost	The therapeutic efficacy of Limaprost can be decreased when used in combination with Salicylamide.	Approved, Investigational
Lisinopril	The risk or severity of adverse effects can be increased when Salicylamide is combined with Lisinopril.	Approved, Investigational
Lisofylline	The risk or severity of adverse effects can be increased when Salicylamide is combined with Lisofylline.	Investigational
Lithium cation	The serum concentration of Lithium can be increased when it is combined with Salicylamide.	Experimental
Lomefloxacin	Salicylamide may increase the neuroexcitatory activities of Lomefloxacin.	Approved, Investigational
Lonazolac	The risk or severity of adverse effects can be increased when Salicylamide is combined with Lonazolac.	Experimental
Lornoxicam	The risk or severity of adverse effects can be increased when Salicylamide is combined with Lornoxicam.	Approved, Investigational
Losartan	The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Salicylamide.	Approved
Loteprednol	The risk or severity of adverse effects can be increased when Salicylamide is combined with Loteprednol.	Approved
Loxoprofen	The risk or severity of adverse effects can be increased when Salicylamide is combined with Loxoprofen.	Approved, Investigational
Lubiprostone	The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Salicylamide.	Approved, Investigational
Lumiracoxib	The risk or severity of adverse effects can be increased when Salicylamide is combined with Lumiracoxib.	Approved, Investigational
Luprostiol	The therapeutic efficacy of Luprostiol can be decreased when used in combination with Salicylamide.	Vet Approved
Magnesium salicylate	The risk or severity of adverse effects can be increased when Salicylamide is combined with Magnesium salicylate.	Approved
Manidipine	The therapeutic efficacy of Manidipine can be decreased when used in combination with Salicylamide.	Approved, Investigational
Masoprocol	The risk or severity of adverse effects can be increased when Masoprocol is combined with Salicylamide.	Approved, Investigational
ME-609	The risk or severity of adverse effects can be increased when Salicylamide is combined with ME-609.	Investigational
Meclofenamic acid	The risk or severity of adverse effects can be increased when Salicylamide is combined with Meclofenamic acid.	Approved, Vet Approved
Medrysone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Medrysone.	Approved
Mefenamic acid	The risk or severity of adverse effects can be increased when Salicylamide is combined with Mefenamic acid.	Approved
Melagatran	Salicylamide may increase the anticoagulant activities of Melagatran.	Experimental
Melengestrol	The risk or severity of adverse effects can be increased when Salicylamide is combined with Melengestrol.	Vet Approved
Meloxicam	The risk or severity of adverse effects can be increased when Salicylamide is combined with Meloxicam.	Approved, Vet Approved
Mepindolol	Salicylamide may decrease the antihypertensive activities of Mepindolol.	Experimental
Mesalazine	The risk or severity of adverse effects can be increased when Salicylamide is combined with Mesalazine.	Approved
Metamizole	The risk or severity of adverse effects can be increased when Metamizole is combined with Salicylamide.	Approved, Investigational, Withdrawn
Methotrexate	The serum concentration of Methotrexate can be increased when it is combined with Salicylamide.	Approved
Methyclothiazide	The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Salicylamide.	Approved
Methylprednisolone	The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Salicylamide.	Approved, Vet Approved
Metipranolol	Salicylamide may decrease the antihypertensive activities of Metipranolol.	Approved
Metolazone	The therapeutic efficacy of Metolazone can be decreased when used in combination with Salicylamide.	Approved
Metoprolol	Salicylamide may decrease the antihypertensive activities of Metoprolol.	Approved, Investigational
Mibefradil	The therapeutic efficacy of Mibefradil can be decreased when used in combination with Salicylamide.	Investigational, Withdrawn
Micronomicin	Salicylamide may decrease the excretion rate of Micronomicin which could result in a higher serum level.	Experimental
Mifamurtide	The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Salicylamide.	Approved, Experimental
Minoxidil	The therapeutic efficacy of Minoxidil can be decreased when used in combination with Salicylamide.	Approved, Investigational
Misoprostol	The therapeutic efficacy of Misoprostol can be decreased when used in combination with Salicylamide.	Approved
Mizoribine	The risk or severity of adverse effects can be increased when Salicylamide is combined with Mizoribine.	Investigational
Moexipril	The risk or severity of adverse effects can be increased when Salicylamide is combined with Moexipril.	Approved
Mofebutazone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Mofebutazone.	Experimental
Mometasone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Mometasone.	Approved, Vet Approved
Morniflumate	The risk or severity of adverse effects can be increased when Morniflumate is combined with Salicylamide.	Approved
Moxifloxacin	Salicylamide may increase the neuroexcitatory activities of Moxifloxacin.	Approved, Investigational
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Salicylamide.	Approved, Investigational
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Salicylamide.	Approved
Nabumetone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Nabumetone.	Approved
Nadolol	Salicylamide may decrease the antihypertensive activities of Nadolol.	Approved
Nadroparin	Salicylamide may increase the anticoagulant activities of Nadroparin.	Approved, Investigational
Nafamostat	Salicylamide may increase the anticoagulant activities of Nafamostat.	Approved, Investigational
Naftifine	The risk or severity of adverse effects can be increased when Naftifine is combined with Salicylamide.	Approved
Naftopidil	The therapeutic efficacy of Naftopidil can be decreased when used in combination with Salicylamide.	Investigational
Nalidixic Acid	Salicylamide may increase the neuroexcitatory activities of Nalidixic Acid.	Approved, Investigational
Naproxen	The risk or severity of adverse effects can be increased when Naproxen is combined with Salicylamide.	Approved, Vet Approved
NCX 1022	The risk or severity of adverse effects can be increased when Salicylamide is combined with NCX 1022.	Investigational
Neamine	Salicylamide may decrease the excretion rate of Neamine which could result in a higher serum level.	Experimental
Nebivolol	Salicylamide may decrease the antihypertensive activities of Nebivolol.	Approved, Investigational
Nemonoxacin	Salicylamide may increase the neuroexcitatory activities of Nemonoxacin.	Investigational
Neomycin	The risk or severity of nephrotoxicity can be increased when Salicylamide is combined with Neomycin.	Approved, Vet Approved
Nepafenac	The risk or severity of adverse effects can be increased when Salicylamide is combined with Nepafenac.	Approved, Investigational
Netilmicin	Salicylamide may decrease the excretion rate of Netilmicin which could result in a higher serum level.	Approved, Investigational
Nicardipine	The therapeutic efficacy of Nicardipine can be decreased when used in combination with Salicylamide.	Approved, Investigational
Nifenazone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Nifenazone.	Experimental
Niflumic Acid	The risk or severity of adverse effects can be increased when Salicylamide is combined with Niflumic Acid.	Approved
Niguldipine	The therapeutic efficacy of Niguldipine can be decreased when used in combination with Salicylamide.	Experimental
Nilvadipine	The therapeutic efficacy of Nilvadipine can be decreased when used in combination with Salicylamide.	Approved, Investigational
Nimesulide	The risk or severity of adverse effects can be increased when Nimesulide is combined with Salicylamide.	Approved, Investigational, Withdrawn
Nimodipine	The therapeutic efficacy of Nimodipine can be decreased when used in combination with Salicylamide.	Approved, Investigational
Nisoldipine	The therapeutic efficacy of Nisoldipine can be decreased when used in combination with Salicylamide.	Approved
Nitrendipine	The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Salicylamide.	Approved, Investigational
Nitroaspirin	The risk or severity of adverse effects can be increased when Salicylamide is combined with Nitroaspirin.	Investigational
Norfloxacin	Salicylamide may increase the neuroexcitatory activities of Norfloxacin.	Approved
Ofloxacin	Salicylamide may increase the neuroexcitatory activities of Ofloxacin.	Approved
Oleoyl-estrone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Oleoyl-estrone.	Investigational
Olmesartan	The risk or severity of adverse effects can be increased when Olmesartan is combined with Salicylamide.	Approved, Investigational
Olopatadine	The risk or severity of adverse effects can be increased when Olopatadine is combined with Salicylamide.	Approved
Olsalazine	Salicylamide may increase the nephrotoxic activities of Olsalazine.	Approved
Omacetaxine mepesuccinate	The risk or severity of bleeding can be increased when Salicylamide is combined with Omacetaxine mepesuccinate.	Approved, Investigational
Omapatrilat	The risk or severity of adverse effects can be increased when Salicylamide is combined with Omapatrilat.	Investigational
Orgotein	The risk or severity of adverse effects can be increased when Salicylamide is combined with Orgotein.	Vet Approved
Otamixaban	Salicylamide may increase the anticoagulant activities of Otamixaban.	Investigational
Oxaprozin	The risk or severity of adverse effects can be increased when Salicylamide is combined with Oxaprozin.	Approved
Oxolinic acid	Salicylamide may increase the neuroexcitatory activities of Oxolinic acid.	Experimental
Oxprenolol	Salicylamide may decrease the antihypertensive activities of Oxprenolol.	Approved
Oxyphenbutazone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Salicylamide.	Approved, Withdrawn
Palmidrol	The risk or severity of adverse effects can be increased when Salicylamide is combined with Palmidrol.	Experimental, Nutraceutical
Pamidronate	The risk or severity of adverse effects can be increased when Salicylamide is combined with Pamidronate.	Approved
Paramethasone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Paramethasone.	Approved
Parecoxib	The risk or severity of adverse effects can be increased when Salicylamide is combined with Parecoxib.	Approved
Paromomycin	The risk or severity of nephrotoxicity can be increased when Salicylamide is combined with Paromomycin.	Approved, Investigational
Parthenolide	The risk or severity of adverse effects can be increased when Salicylamide is combined with Parthenolide.	Approved, Investigational
Pazufloxacin	Salicylamide may increase the neuroexcitatory activities of Pazufloxacin.	Investigational
Pefloxacin	Salicylamide may increase the neuroexcitatory activities of Pefloxacin.	Approved
Penbutolol	Salicylamide may decrease the antihypertensive activities of Penbutolol.	Approved, Investigational
Pentaerythritol Tetranitrate	Salicylamide may increase the anticoagulant activities of Pentaerythritol Tetranitrate.	Approved
Pentosan Polysulfate	Salicylamide may increase the anticoagulant activities of Pentosan Polysulfate.	Approved
Perindopril	The risk or severity of adverse effects can be increased when Salicylamide is combined with Perindopril.	Approved
Phenindione	Salicylamide may increase the anticoagulant activities of Phenindione.	Approved, Investigational
Phenprocoumon	Salicylamide may increase the anticoagulant activities of Phenprocoumon.	Approved, Investigational
Phenylbutazone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Phenylbutazone.	Approved, Vet Approved
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Salicylamide.	Approved, Investigational
Pindolol	Salicylamide may decrease the antihypertensive activities of Pindolol.	Approved, Investigational
Pipemidic acid	Salicylamide may increase the neuroexcitatory activities of Pipemidic acid.	Experimental
Piretanide	The therapeutic efficacy of Piretanide can be decreased when used in combination with Salicylamide.	Approved
Pirfenidone	The risk or severity of adverse effects can be increased when Pirfenidone is combined with Salicylamide.	Approved, Investigational
Piromidic acid	Salicylamide may increase the neuroexcitatory activities of Piromidic acid.	Experimental
Piroxicam	The risk or severity of adverse effects can be increased when Salicylamide is combined with Piroxicam.	Approved, Investigational
Pirprofen	The risk or severity of adverse effects can be increased when Salicylamide is combined with Pirprofen.	Experimental
Pitolisant	The risk or severity of adverse effects can be increased when Salicylamide is combined with Pitolisant.	Approved, Investigational
Platelet Activating Factor	Salicylamide may decrease the antihypertensive activities of Platelet Activating Factor.	Experimental
Plazomicin	Salicylamide may decrease the excretion rate of Plazomicin which could result in a higher serum level.	Approved, Investigational
Polythiazide	The therapeutic efficacy of Polythiazide can be decreased when used in combination with Salicylamide.	Approved
Pomalidomide	The risk or severity of adverse effects can be increased when Salicylamide is combined with Pomalidomide.	Approved
Potassium Citrate	Salicylamide may increase the anticoagulant activities of Potassium Citrate.	Approved, Investigational, Vet Approved
Practolol	Salicylamide may decrease the antihypertensive activities of Practolol.	Approved
Pralatrexate	The serum concentration of Pralatrexate can be increased when it is combined with Salicylamide.	Approved, Investigational
Pranoprofen	The risk or severity of adverse effects can be increased when Salicylamide is combined with Pranoprofen.	Experimental, Investigational
Prasterone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Prasterone.	Approved, Investigational, Nutraceutical
Prasterone sulfate	The risk or severity of adverse effects can be increased when Salicylamide is combined with Prasterone sulfate.	Investigational
Prednicarbate	The risk or severity of adverse effects can be increased when Salicylamide is combined with Prednicarbate.	Approved, Investigational
Prednisolone	The risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Salicylamide.	Approved, Vet Approved
Prednisone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Prednisone.	Approved, Vet Approved
Pregnenolone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Pregnenolone.	Approved, Experimental, Investigational
Probenecid	The serum concentration of Salicylamide can be increased when it is combined with Probenecid.	Approved, Investigational
Proglumetacin	The risk or severity of adverse effects can be increased when Salicylamide is combined with Proglumetacin.	Experimental
Propacetamol	The risk or severity of adverse effects can be increased when Salicylamide is combined with Propacetamol.	Approved, Investigational
Propafenone	Salicylamide may decrease the antihypertensive activities of Propafenone.	Approved
Propranolol	Salicylamide may decrease the antihypertensive activities of Propranolol.	Approved, Investigational
Propyphenazone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Propyphenazone.	Experimental
Proquazone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Proquazone.	Experimental
Prostaglandin B2	The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Salicylamide.	Experimental
Prostaglandin G2	The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Salicylamide.	Experimental
Prostalene	The therapeutic efficacy of Prostalene can be decreased when used in combination with Salicylamide.	Vet Approved
Protein C	Salicylamide may increase the anticoagulant activities of Protein C.	Approved
Protein S human	Salicylamide may increase the anticoagulant activities of Protein S human.	Approved
Protocatechualdehyde	Salicylamide may increase the anticoagulant activities of Protocatechualdehyde.	Approved
Prulifloxacin	Salicylamide may increase the neuroexcitatory activities of Prulifloxacin.	Investigational
PTC299	The risk or severity of adverse effects can be increased when PTC299 is combined with Salicylamide.	Investigational
Puromycin	Salicylamide may decrease the excretion rate of Puromycin which could result in a higher serum level.	Experimental
Quinapril	The risk or severity of adverse effects can be increased when Salicylamide is combined with Quinapril.	Approved, Investigational
Quinethazone	The therapeutic efficacy of Quinethazone can be decreased when used in combination with Salicylamide.	Approved
Ramipril	The risk or severity of adverse effects can be increased when Salicylamide is combined with Ramipril.	Approved
Rescinnamine	The risk or severity of adverse effects can be increased when Salicylamide is combined with Rescinnamine.	Approved
Resveratrol	The risk or severity of adverse effects can be increased when Salicylamide is combined with Resveratrol.	Approved, Experimental, Investigational
Reviparin	Salicylamide may increase the anticoagulant activities of Reviparin.	Approved, Investigational
Ribostamycin	Salicylamide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.	Approved, Investigational
Rimexolone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Rimexolone.	Approved
Risedronate	The risk or severity of adverse effects can be increased when Salicylamide is combined with Risedronate.	Approved, Investigational
Rivaroxaban	Salicylamide may increase the anticoagulant activities of Rivaroxaban.	Approved
Rofecoxib	The risk or severity of adverse effects can be increased when Salicylamide is combined with Rofecoxib.	Approved, Investigational, Withdrawn
Rosoxacin	Salicylamide may increase the neuroexcitatory activities of Rosoxacin.	Approved, Investigational
Rufloxacin	Salicylamide may increase the neuroexcitatory activities of Rufloxacin.	Experimental
Sacubitril	The risk or severity of adverse effects can be increased when Sacubitril is combined with Salicylamide.	Approved
Salicylic acid	The risk or severity of adverse effects can be increased when Salicylic acid is combined with Salicylamide.	Approved, Investigational, Vet Approved
Salsalate	The risk or severity of adverse effects can be increased when Salicylamide is combined with Salsalate.	Approved
Saprisartan	The risk or severity of adverse effects can be increased when Saprisartan is combined with Salicylamide.	Experimental
Saralasin	The risk or severity of adverse effects can be increased when Saralasin is combined with Salicylamide.	Investigational
Sarilumab	Sarilumab may increase the immunosuppressive activities of Salicylamide.	Approved, Investigational
Seliciclib	The risk or severity of adverse effects can be increased when Salicylamide is combined with Seliciclib.	Investigational
Semapimod	The risk or severity of adverse effects can be increased when Salicylamide is combined with Semapimod.	Investigational
Seratrodast	The risk or severity of adverse effects can be increased when Seratrodast is combined with Salicylamide.	Approved
Serrapeptase	The risk or severity of adverse effects can be increased when Salicylamide is combined with Serrapeptase.	Investigational
Sisomicin	Salicylamide may decrease the excretion rate of Sisomicin which could result in a higher serum level.	Investigational
Sitafloxacin	Salicylamide may increase the neuroexcitatory activities of Sitafloxacin.	Experimental, Investigational
Sodium Citrate	The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Sodium Citrate.	Approved, Investigational
Sodium phosphate, monobasic	The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Salicylamide.	Approved
Sotalol	Salicylamide may decrease the antihypertensive activities of Sotalol.	Approved
Sparfloxacin	Salicylamide may increase the neuroexcitatory activities of Sparfloxacin.	Approved, Investigational
Spirapril	The risk or severity of adverse effects can be increased when Salicylamide is combined with Spirapril.	Approved
Spironolactone	The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylamide is combined with Spironolactone.	Approved
SRT501	The risk or severity of adverse effects can be increased when SRT501 is combined with Salicylamide.	Investigational
Streptomycin	Salicylamide may decrease the excretion rate of Streptomycin which could result in a higher serum level.	Approved, Vet Approved
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Salicylamide.	Approved
Sulindac	The risk or severity of adverse effects can be increased when Sulindac is combined with Salicylamide.	Approved, Investigational
Sulodexide	Salicylamide may increase the anticoagulant activities of Sulodexide.	Approved, Investigational
Sulprostone	The therapeutic efficacy of Sulprostone can be decreased when used in combination with Salicylamide.	Investigational
Suprofen	The risk or severity of adverse effects can be increased when Salicylamide is combined with Suprofen.	Approved, Withdrawn
Suxibuzone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Suxibuzone.	Experimental
Tacrolimus	Salicylamide may increase the nephrotoxic activities of Tacrolimus.	Approved, Investigational
Tafluprost	The therapeutic efficacy of Tafluprost can be decreased when used in combination with Salicylamide.	Approved
Talinolol	Salicylamide may decrease the antihypertensive activities of Talinolol.	Investigational
Talniflumate	The risk or severity of adverse effects can be increased when Talniflumate is combined with Salicylamide.	Approved
Tarenflurbil	The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Salicylamide.	Investigational
Tasosartan	The risk or severity of adverse effects can be increased when Tasosartan is combined with Salicylamide.	Approved
Technetium Tc-99m etidronate	The risk or severity of adverse effects can be increased when Salicylamide is combined with Technetium Tc-99m etidronate.	Approved
Technetium Tc-99m medronate	The risk or severity of adverse effects can be increased when Salicylamide is combined with Technetium Tc-99m medronate.	Approved
Telmisartan	The risk or severity of adverse effects can be increased when Telmisartan is combined with Salicylamide.	Approved, Investigational
Temafloxacin	Salicylamide may increase the neuroexcitatory activities of Temafloxacin.	Withdrawn
Temocapril	The risk or severity of adverse effects can be increased when Salicylamide is combined with Temocapril.	Experimental, Investigational
Tenidap	The risk or severity of adverse effects can be increased when Salicylamide is combined with Tenidap.	Experimental
Tenofovir disoproxil	The risk or severity of adverse effects can be increased when Salicylamide is combined with Tenofovir disoproxil.	Approved, Investigational
Tenoxicam	The risk or severity of adverse effects can be increased when Salicylamide is combined with Tenoxicam.	Approved
Tepoxalin	The risk or severity of adverse effects can be increased when Salicylamide is combined with Tepoxalin.	Vet Approved
Terbutaline	Salicylamide may decrease the antihypertensive activities of Terbutaline.	Approved
Teriflunomide	The risk or severity of adverse effects can be increased when Salicylamide is combined with Teriflunomide.	Approved
Tertatolol	Salicylamide may decrease the antihypertensive activities of Tertatolol.	Experimental
Tetrahydropalmatine	The therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Salicylamide.	Investigational
Tiaprofenic acid	The risk or severity of adverse effects can be increased when Salicylamide is combined with Tiaprofenic acid.	Approved
Tiludronic acid	The risk or severity of adverse effects can be increased when Salicylamide is combined with Tiludronic acid.	Approved, Investigational, Vet Approved
Timolol	Salicylamide may decrease the antihypertensive activities of Timolol.	Approved
Tinoridine	The risk or severity of adverse effects can be increased when Salicylamide is combined with Tinoridine.	Investigational
Tixocortol	The risk or severity of adverse effects can be increased when Salicylamide is combined with Tixocortol.	Approved, Withdrawn
Tobramycin	Salicylamide may decrease the excretion rate of Tobramycin which could result in a higher serum level.	Approved, Investigational
Tolfenamic Acid	The risk or severity of adverse effects can be increased when Salicylamide is combined with Tolfenamic Acid.	Approved, Investigational
Tolmetin	The risk or severity of adverse effects can be increased when Salicylamide is combined with Tolmetin.	Approved
Torasemide	The therapeutic efficacy of Torasemide can be decreased when used in combination with Salicylamide.	Approved
Trandolapril	The risk or severity of adverse effects can be increased when Salicylamide is combined with Trandolapril.	Approved
Travoprost	The therapeutic efficacy of Travoprost can be decreased when used in combination with Salicylamide.	Approved
Treprostinil	The risk or severity of adverse effects can be increased when Treprostinil is combined with Salicylamide.	Approved, Investigational
Triamcinolone	The risk or severity of adverse effects can be increased when Salicylamide is combined with Triamcinolone.	Approved, Vet Approved
Triamterene	Salicylamide may decrease the antihypertensive activities of Triamterene.	Approved
Tribenoside	The risk or severity of adverse effects can be increased when Salicylamide is combined with Tribenoside.	Experimental
Trichlormethiazide	The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Salicylamide.	Approved, Vet Approved
Triptolide	The risk or severity of adverse effects can be increased when Salicylamide is combined with Triptolide.	Investigational
Trolamine salicylate	The risk or severity of adverse effects can be increased when Salicylamide is combined with Trolamine salicylate.	Approved
Trovafloxacin	Salicylamide may increase the neuroexcitatory activities of Trovafloxacin.	Approved, Investigational, Withdrawn
Troxerutin	Salicylamide may increase the anticoagulant activities of Troxerutin.	Investigational
Ulobetasol	The risk or severity of adverse effects can be increased when Salicylamide is combined with Ulobetasol.	Approved
Unoprostone	The therapeutic efficacy of Unoprostone can be decreased when used in combination with Salicylamide.	Approved, Investigational
Valdecoxib	The risk or severity of adverse effects can be increased when Salicylamide is combined with Valdecoxib.	Approved, Investigational, Withdrawn
Valsartan	The risk or severity of adverse effects can be increased when Valsartan is combined with Salicylamide.	Approved, Investigational
Vancomycin	Salicylamide may decrease the excretion rate of Vancomycin which could result in a higher serum level.	Approved
Warfarin	Salicylamide may increase the anticoagulant activities of Warfarin.	Approved
Ximelagatran	Salicylamide may increase the anticoagulant activities of Ximelagatran.	Approved, Investigational, Withdrawn
Zaltoprofen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Salicylamide.	Approved, Investigational
Zileuton	The risk or severity of adverse effects can be increased when Zileuton is combined with Salicylamide.	Approved, Investigational, Withdrawn
Zofenopril	The risk or severity of adverse effects can be increased when Salicylamide is combined with Zofenopril.	Experimental
Zoledronic acid	The risk or severity of gastrointestinal bleeding can be increased when Salicylamide is combined with Zoledronic acid.	Approved
Zomepirac	The risk or severity of adverse effects can be increased when Zomepirac is combined with Salicylamide.	Withdrawn

Food Interactions

Not Available

References

Synthesis Reference

Elijah J. Gold, Esther Babad, Lydia Peer, Wei K. Chang, "Preparation of (-)-5-(beta)-1-hydroxy-2-((beta)-1-methyl-3-phenylpropyl)aminoethyl) salicylamide." U.S. Patent US4658060, issued November, 1979.

US4658060

General References

Not Available

External Links

Human Metabolome Database: HMDB0015687
PubChem Compound: 5147
PubChem Substance: 99445267
ChemSpider: 4963
BindingDB: 50056900
ChEBI: 32114
ChEMBL: CHEMBL27577
HET: OHB
Wikipedia: Salicylamide

ATC Codes

N02BA75 — Salicylamide, combinations with psycholeptics

N02BA05 — Salicylamide

N02BA55 — Salicylamide, combinations excl. psycholeptics

PDB Entries

4k17

MSDS

Download (57 KB)

Clinical Trials

Clinical Trials: Not Available

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Form	Route	Strength
Tablet	Oral

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	142 °C	PhysProp
boiling point (°C)	181.5 °C	PhysProp
water solubility	2060 mg/L (at 25 °C)	YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP	1.28	HANSCH,C ET AL. (1995)
pKa	8.37 (at 20 °C)	KORTUM,G ET AL (1961)

Predicted Properties

Property	Value	Source
Water Solubility	7.82 mg/mL	ALOGPS
logP	0.74	ALOGPS
logP	1.17	ChemAxon
logS	-1.2	ALOGPS
pKa (Strongest Acidic)	8.21	ChemAxon
pKa (Strongest Basic)	-1.8	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	2	ChemAxon
Hydrogen Donor Count	2	ChemAxon
Polar Surface Area	63.32 Å²	ChemAxon
Rotatable Bond Count	1	ChemAxon
Refractivity	37.12 m³·mol^-1	ChemAxon
Polarizability	13.22 Å³	ChemAxon
Number of Rings	1	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9877
Blood Brain Barrier	+	0.9382
Caco-2 permeable	+	0.6048
P-glycoprotein substrate	Non-substrate	0.8565
P-glycoprotein inhibitor I	Non-inhibitor	0.9817
P-glycoprotein inhibitor II	Non-inhibitor	0.9948
Renal organic cation transporter	Non-inhibitor	0.9178
CYP450 2C9 substrate	Non-substrate	0.8207
CYP450 2D6 substrate	Non-substrate	0.6203
CYP450 3A4 substrate	Non-substrate	0.7067
CYP450 1A2 substrate	Non-inhibitor	0.7061
CYP450 2C9 inhibitor	Non-inhibitor	0.952
CYP450 2D6 inhibitor	Non-inhibitor	0.9043
CYP450 2C19 inhibitor	Non-inhibitor	0.8779
CYP450 3A4 inhibitor	Non-inhibitor	0.8828
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9144
Ames test	Non AMES toxic	0.9133
Carcinogenicity	Non-carcinogens	0.864
Biodegradation	Ready biodegradable	0.7192
Rat acute toxicity	2.1150 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9867
hERG inhibition (predictor II)	Non-inhibitor	0.9468

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
GC-MS Spectrum - EI-B	GC-MS	splash10-00du-4900000000-f5a22e5a4fb556796bd9
GC-MS Spectrum - EI-B	GC-MS	splash10-00du-8900000000-701c75263149bd35390b
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
MS/MS Spectrum - , negative	LC-MS/MS	splash10-000i-1900000000-132217380eb9a2784eb0

Taxonomy

Description: This compound belongs to the class of organic compounds known as 1-hydroxy-4-unsubstituted benzenoids. These are phenols that are unsubstituted at the 4-position.
Kingdom: Organic compounds
Super Class: Benzenoids
Class: Phenols
Sub Class: 1-hydroxy-4-unsubstituted benzenoids
Direct Parent: 1-hydroxy-4-unsubstituted benzenoids
Alternative Parents: 1-hydroxy-2-unsubstituted benzenoids / Benzene and substituted derivatives / Carboximidic acids / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Hydrocarbon derivatives
Substituents: 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Monocyclic benzene moiety / Carboximidic acid derivative / Carboximidic acid / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Hydrocarbon derivative / Organooxygen compound
Molecular Framework: Aromatic homomonocyclic compounds
External Descriptors: phenols, salicylamides (CHEBI:32114) / a small molecule (SALICYLAMIDE)

Drug created on October 08, 2010 16:10 / Updated on August 02, 2018 06:10

Salicylamide

Identification

Structure for DB08797 (Salicylamide)

Pharmacology

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy